Sort   by:  
 Page size 
ProteomicsAZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells
Phosphorylation of RNA polymerase II by cyclin-dependent kinase 9 (CDK9) is crucial for transcriptional regulation, and acute inhibition of CDK9 results in the rapid downregulation of genes with short-lived transcripts and labile proteins. Multiple non-selective CDK9 inhibitors have progressed clini...
ORGANISM(S): Homo sapiens (Human) 
2020-05-26 | PXD013796 | Pride
A selective cdk9 inhibitor Azd4573 Targets mcl-1 
TranscriptomicsExpression profiling of HeLa cell line treated with CDK9 inhibitor
CDK9 is the kinase subunit of P-TEFb that enables RNA polymerase (Pol) II to transit from promoter-proximal pausing to productive elongation. Although considerable interest exists in CDK9 as a therapeutic target, little progress has been made due to the lack of highly selective inhibitors. Here, we ...
ORGANISM(S): Homo sapiens 
2015-06-17 | E-GEOD-60952 | biostudies-arrayexpress
GenomicsTargeting Transcriptional Addiction by a Novel Highly Selective CDK9 Kinase Inhibitor for AML.
Targeting Transcriptional Addiction by a Novel Highly Selective CDK9 Kinase Inhibitor for AML.
PRJNA508101 | ENA
GenomicsCompensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism: Pol II occupancy profiling by ChIP-Seq in HeLa cell line in the presence or absence of CDK9 inhibition
CDK9 is the kinase subunit of P-TEFb that enables RNA polymerase (Pol) II to transit from promoter-proximal pausing to productive elongation. Although considerable interest exists in CDK9 as a therapeutic target, little progress has been made due to the lack of highly selective inhibitors. Here, we ...
ORGANISM(S): Homo sapiens 
2015-06-17 | E-GEOD-60953 | biostudies-arrayexpress
GenomicsDevelopment of a selective CDK9 degrader from a multi-targeted CDK inhibitor [ChIP-seq]
Cyclin dependent kinase 9 (CDK9), a key regulator of transcriptional elongation, has long been considered a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. However, despite promising early clinical data in blood cancers using pan-CDK inhibitors ...
ORGANISM(S): Homo sapiens 
2017-09-01 | GSE89384 | GEO
TranscriptomicsDevelopment of a selective CDK9 degrader from a multi-targeted CDK inhibitor [RNA-seq]
Cyclin dependent kinase 9 (CDK9), a key regulator of transcriptional elongation, has long been considered a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. However, despite promising early clinical data in blood cancers using pan-CDK inhibitors ...
ORGANISM(S): Homo sapiens 
2017-09-01 | GSE89385 | GEO
GenomicsRNA-seq data corresponding to: AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells
RNA-seq data corresponding to: AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells
PRJNA529703 | ENA
GenomicsDevelopment of a selective CDK9 degrader from a multi-targeted CDK inhibitor
Development of a selective CDK9 degrader from a multi-targeted CDK inhibitor
PRJNA352041 | ENA
GenomicsVIP152 is a Selective CDK9 Inhibitor with Pre-Clinical In Vitro and In Vivo Efficacy in Chronic Lymphocytic Leukemia
VIP152 is a Selective CDK9 Inhibitor with Pre-Clinical In Vitro and In Vivo Efficacy in Chronic Lymphocytic Leukemia
PRJNA818165 | ENA
ProteomicsTargeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Cyclin-Dependent Kinase 9 (CDK9) as part of the PTEFb complex promotes transcriptional elongation by promoting RNAPII pause release. We now report that, paradoxically, CDK9 is also essential for maintaining gene silencing at heterochromatic loci. Through a live cell screen, we discovered that CDK9 i...
ORGANISM(S): Mus musculus (Mouse) 
2020-05-26 | PXD007925 | Pride
Cdk9 Epigenetic therapy Immunosensitization Gene silencing 
Sort   by:  
 Page size